Local view for "http://purl.org/linkedpolitics/eu/plenary/2008-10-22-Speech-3-989"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2008-10-22"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"pl"^^xsd:language2
lpv:document identification number	"en.20081022.17.3-989"2
lpv:hasSubsequent	lp_eu:2008-10-22-Speech-3-2302
lpv:speaker	lp:Bernard Wojciechowski2
lpv:spokenAs	member; AFCO (2007-01-31--2009-07-13)3 unknown; - (2007-04-16--2009-07-13)3 member; Delegation for relations with Belarus (2007-03-14--2009-07-13)3 member_of_the_bureau; IND/DEM (2008-01-30--2009-07-13)3 member; DROI (2008-05-21--2009-07-13)3 substitute; AFET (2008-05-20--2009-07-13)3
lpv:translated text	"( Given the lack of harmonisation at Community level, variations to purely domestic marketing authorisations are subject to national legislation. In some Member States, the requirements relating to national marketing authorisations are analogous to those relating to variations in marketing authorisations. However, in the majority of countries, there is no such coordination, which means that legislative discrepancies exist between the Member States. This situation has a negative impact in terms of public health, the administrative burden and the general operation of the internal market for pharmaceutical products. All medicinal products, regardless of the marketing authorisation criteria, should be subject to the same evaluation criteria and to the same administrative measures when their marketing authorisation differs."@en1
lpv:unclassifiedMetadata	"Bernard Wojciechowski (IND/DEM ),"1 "PL)"1 "in writing."1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph